Cargando…

Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide and High-Sensitivity Troponin T Levels in the Natural History of Transthyretin Amyloid Cardiomyopathy and Their Evolution after Tafamidis Treatment

Background: We assesse the evolution and prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (cTnT-HS) in transthyretin amyloid cardiomyopathy (ATTR-CA) before and after tafamidis treatment. Methods and Results: 454 ATTR-CA patients without tafami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oghina, Silvia, Josse, Constant, Bézard, Mélanie, Kharoubi, Mounira, Delbarre, Marc-Antoine, Eyharts, Damien, Zaroui, Amira, Guendouz, Soulef, Galat, Arnault, Hittinger, Luc, Fanen, Pascale, Teiger, Emmanuel, Mouri, Nadir, Montestruc, François, Damy, Thibaud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584290/ https://www.ncbi.nlm.nih.gov/pubmed/34768388 http://dx.doi.org/10.3390/jcm10214868

Ejemplares similares

Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild‐type cardiac amyloidosis
por: Kharoubi, Mounira, et al.
Publicado: (2020)

Prevalence and determinants of iron deficiency in cardiac amyloidosis
por: Jobbé‐Duval, Antoine, et al.
Publicado: (2022)

Echocardiographic Patterns of Left Ventricular Diastolic Function in Cardiac Amyloidosis: An Updated Evaluation
por: Oghina, Silvia, et al.
Publicado: (2021)

Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement
por: Bézard, Mélanie, et al.
Publicado: (2021)

History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis
por: Kharoubi, Mounira, et al.
Publicado: (2021)

Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis
por: Kharoubi, Mounira, et al.
Publicado: (2023)

Frailty in Wild-Type Transthyretin Cardiac Amyloidosis: The Tip of the Iceberg
por: Broussier, Amaury, et al.
Publicado: (2021)

Reply to the letter regarding the article ‘Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study’
por: Damy, Thibaud, et al.
Publicado: (2021)

Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study
por: Damy, Thibaud, et al.
Publicado: (2020)

Heart Transplantation, Either Alone or Combined With Liver and Kidney, a Viable Treatment Option for Selected Patients With Severe Cardiac Amyloidosis
por: Guendouz, Soulef, et al.
Publicado: (2022)

Myocardial Gene Expression Profiling to Predict and Identify Cardiac Allograft Acute Cellular Rejection: The GET-Study
por: Bodez, Diane, et al.
Publicado: (2016)

Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms
por: Gonzalez-Lopez, Esther, et al.
Publicado: (2022)

Pulmonary hemodynamic responses to inhaled NO in chronic heart failure depend on PDE5 G(-1142)T polymorphism
por: Damy, Thibaud, et al.
Publicado: (2011)

Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
por: Li, Benjamin, et al.
Publicado: (2020)

A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis
por: Waddington Cruz, Márcia, et al.
Publicado: (2015)

Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy
por: Romero-Imbroda, Jesús, et al.
Publicado: (2017)

Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
por: Nakamura, Makiko, et al.
Publicado: (2020)

Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis
por: Damy, Thibaud, et al.
Publicado: (2015)

Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy
por: Falk, Rodney H., et al.
Publicado: (2021)

Evaluation of a new ELISA assay for monoclonal free‐light chain detection in patients with cardiac amyloidosis
por: Abroud, Hajer, et al.
Publicado: (2022)

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2016)

A Systematic Review of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Singh, Bishnu Mohan, et al.
Publicado: (2021)

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Elliott, Perry, et al.
Publicado: (2021)

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis
por: Law, Steven, et al.
Publicado: (2022)

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
por: Coelho, Teresa, et al.
Publicado: (2013)

Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy
por: Sultan, Marla B, et al.
Publicado: (2017)

Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review
por: Cruz, Márcia Waddington
Publicado: (2019)

Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy
por: Rettl, René, et al.
Publicado: (2023)

Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis
por: Merlini, Giampaolo, et al.
Publicado: (2013)

Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies
por: Rozenbaum, Mark H, et al.
Publicado: (2021)

Monitoring Tafamidis, The Most Expensive Cardiac Medication: Are Serum Transthyretin Levels the Answer?
por: Chang, Ian C., et al.
Publicado: (2021)

Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis
por: Giblin, Gerard T, et al.
Publicado: (2022)

Tafamidis and tafamidis meglumine for amyloid cardiomyopathy
Publicado: (2021)

Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
por: Rozenbaum, Mark H., et al.
Publicado: (2022)

Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy
por: Falcão de Campos, Catarina, et al.
Publicado: (2023)

Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis
por: Wang, Jie, et al.
Publicado: (2023)

Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild‐type transthyretin amyloid cardiomyopathy
por: Takashio, Seiji, et al.
Publicado: (2023)

Positive real-world effectiveness of tafamidis for delaying disease progression in transthyretin familial amyloid polyneuropathy
por: Stewart, Michelle, et al.
Publicado: (2015)

Post Hoc Analysis of Nutritional Status in Patients with Transthyretin Familial Amyloid Polyneuropathy: Impact of Tafamidis
por: Suhr, Ole B., et al.
Publicado: (2014)

Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy
por: Shintani, Yasuhiro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0p9gvr3u4qc6j1oq1vacc7k4ek